[Skip to Content]
[Skip to Content Landing]

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion

Educational Objective
To understand how Medicaid expansion influenced buprenorphine treatment for opioid use disorder.
1 Credit CME
Key Points

Question  Did Medicaid expansion under the US Affordable Care Act change prescription fills for buprenorphine with naloxone, a treatment for opioid use disorder, and opioid pain relievers?

Findings  In this cohort study using difference-in-differences analysis of all-payer prescription fill data from 5 states, Medicaid expansion was associated with a significant overall increase in people filling prescriptions for buprenorphine with naloxone. Expansion was not associated with changes in fills per 100 000 county residents of opioid pain relievers overall, but significantly more people filled prescriptions for opioid pain relievers paid for specifically by Medicaid.

Meaning  Medicaid expansion may increase the role of states in providing opioid use disorder treatment and in paying for opioid pain relievers for pain management.

Abstract

Importance  Expanding Medicaid eligibility could affect prescriptions of buprenorphine with naloxone, an established treatment for opioid use disorder, and opioid pain relievers (OPRs).

Objective  To examine changes in prescriptions of buprenorphine with naloxone and OPRs after the US Affordable Care Act Medicaid expansion.

Design, Setting, and Participants  In this cohort study, longitudinal, patient-level, retail pharmacy claims were extracted from IQVIA real-world data from an anonymized, longitudinal, prescription database. The sample included 11.9 million individuals who filled 2 or more prescriptions for a prescription opioid during at least 1 year between January 1, 2010, and December 31, 2015, from California, Maryland, and Washington (expansion states) and Florida and Georgia (nonexpansion states). Data analysis was conducted from August 1, 2017, to May 31, 2018. Data were aggregated to county-year observations (N = 2082) and linked to county-level covariates. For each outcome, a difference-in-differences regression model was estimated comparing changes before and after expansion in expansion vs nonexpansion counties. Models were adjusted for county demographics, uninsured rate, and overdose mortality in the baseline year (2010).

Exposures  Presence of Medicaid expansion in the year.

Main Outcomes and Measures  For buprenorphine with naloxone and OPRs, rates per 100 000 county residents were calculated separately for any prescriptions overall and by different payment sources. Mean days of medication per county among people filling prescriptions for these agents were also determined.

Results  The study sample included 11.9 million individuals (expansion states: 40.9% men; mean [SD] age, 44.1 [13.8] years; nonexpansion states: 41.0% men; mean [SD] age, 43.7 [13.7] years). In expansion counties, 68.8 individuals per 100 000 county residents filled buprenorphine with naloxone and 5298.3 filled OPR prescriptions in 2010. After expansion, buprenorphine with naloxone fills per 100 000 county residents increased significantly in expansion relative to nonexpansion counties (8.7; 95% CI, 1.7 to 15.7). Opioid pain reliever fills per 100 000 county residents did not significantly change in expansion counties relative to nonexpansion counties (327.4; 95% CI −202.5 to 857.4). The rate of OPRs per 100 000 county residents paid for by Medicaid significantly increased (374.0; 95% CI, 258.3 to 489.7). There were no significant changes in days per 100 000 county residents of either medication after expansion.

Conclusions and Relevance  Medicaid expansion significantly increased buprenorphine with naloxone prescriptions per 100 000 county residents in expansion counties, suggesting that expansion improved access to opioid use disorder treatment. Expansion did not significantly increase the overall rate per 100 000 county residents of OPR prescriptions, but increased the population with OPRs paid for by Medicaid. This finding therefore suggests the growing importance of Medicaid in pain management and addiction prevention.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: June 7, 2018.

Published: August 17, 2018. doi:10.1001/jamanetworkopen.2018.1588

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Saloner B et al. JAMA Network Open.

Corresponding Author: Brendan Saloner, PhD, Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 344, Baltimore, MD 21205 (bsaloner@jhu.edu).

Author Contributions: Dr Saloner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Saloner, Jones.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Saloner, Levin.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Saloner, Levin, Chang, Jones.

Obtained funding: Saloner.

Administrative, technical, or material support: Saloner, Alexander.

Supervision: Saloner.

Conflict of Interest Disclosures: Dr Alexander is chair of the US Food and Drug Administration’s Peripheral and Central Nervous System Advisory Committee; has served as a paid consultant to IQVIA; holds an equity share in MesaRx Innovations; holds equity in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and serves as a paid member of OptumRx’s P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. No other disclosures were reported.

Funding/Support: This study was funded by the internal Lipitz Grant at the Johns Hopkins Bloomberg School of Public Health. Dr Saloner also acknowledges funding support from the National Institute on Drug Abuse grant K01 DA042139.

Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Clarke  TC, Ward  BW, Norris  T, Schiller  JS. Early release of selected estimates based on data from the January-September 2016 National Health Interview Survey. https://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201702.pdf. Accessed July 12, 2018.
2.
Hedegaard  H, Warner  M, Miniño  AM.  Drug overdose deaths in the United States, 1999-2016.  NCHS Data Brief. 2017;(294):1-8.PubMedGoogle Scholar
3.
 A Majority Staff Report of the Committee on Homeland Security and Governmental Affairs United States Senate. Drugs for Dollars: How Medicaid Fuels the Opioid Epidemic. Washington, DC: US Senate; 2018.
4.
Goodman-Bacon  A, Sandoe  E. Did Medicaid expansion cause the opioid epidemic? there’s little evidence that it did. https://www.healthaffairs.org/do/10.1377/hblog20170823.061640/full/. Published 2018. Accessed March 1, 2018.
5.
Broaddus  M, Bailey  P, Aron-Dine  A.  Medicaid Expansion Dramatically Increased Coverage for People With Opioid-Use Disorders, Latest Data Show. Washington, DC: Center for Budget and Policy Priorities; 2018. https://www.cbpp.org/research/health/medicaid-expansion-dramatically-increased-coverage-for-people-with-opioid-use. Accessed March 1, 2018.
6.
Sharp  A, Jones  A, Sherwood  J, Kutsa  O, Honermann  B, Millett  G.  Impact of Medicaid Expansion on access to opioid analgesic medications and medication-assisted treatment.  Am J Public Health. 2018;108(5):642-648. doi:10.2105/AJPH.2018.304338PubMedGoogle ScholarCrossref
7.
Barry  CL, Huskamp  HA.  Moving beyond parity—mental health and addiction care under the ACA.  N Engl J Med. 2011;365(11):973-975. doi:10.1056/NEJMp1108649PubMedGoogle ScholarCrossref
8.
Saloner  B, Karthikeyan  S.  Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013.  JAMA. 2015;314(14):1515-1517. doi:10.1001/jama.2015.10345PubMedGoogle ScholarCrossref
9.
Chen  KY, Chen  L, Mao  J.  Buprenorphine-naloxone therapy in pain management.  Anesthesiology. 2014;120(5):1262-1274. doi:10.1097/ALN.0000000000000170PubMedGoogle ScholarCrossref
10.
Roberts  AW, Saloner  B, Dusetzina  SB.  Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015.  Psychiatr Serv. 2018;69(7):832-835. doi:10.1176/appi.ps.201700315PubMedGoogle ScholarCrossref
11.
Wen  H, Hockenberry  JM, Borders  TF, Druss  BG.  Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment.  Med Care. 2017;55(4):336-341. doi:10.1097/MLR.0000000000000703PubMedGoogle ScholarCrossref
12.
Cope  LC, Lynch  V, Epstein  M, Kenney  G.  Medicaid Coverage of Effective Treatment for Opioid Use Disorder Trends in State Buprenorphine Prescriptions and Spending Since 2011. Washington, DC: The Urban Institute; 2017.
13.
Saloner  B, Daubresse  M, Caleb Alexander  G.  Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population.  Med Care. 2017;55(7):669-676. doi:10.1097/MLR.0000000000000727PubMedGoogle ScholarCrossref
14.
Chang  H-Y, Lyapustina  T, Rutkow  L,  et al.  Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: a comparative interrupted time series analysis.  Drug Alcohol Depend. 2016;165:1-8. doi:10.1016/j.drugalcdep.2016.04.033PubMedGoogle ScholarCrossref
15.
Centers for Disease and Control and Prevention. Analyzing prescription data and morphine milligram equivalents (MME). September 2017. https://www.cdc.gov/drugoverdose/resources/data.html. Accessed May 16, 2018.
16.
Golberstein  E, Gonzales  G, Sommers  BD.  California’s early ACA expansion increased coverage and reduced out-of-pocket spending for the state’s low-income population.  Health Aff (Millwood). 2015;34(10):1688-1694. doi:10.1377/hlthaff.2015.0290PubMedGoogle ScholarCrossref
17.
US Census Bureau. American Community Survey (ACS), 2018. https://www.census.gov/programs-surveys/acs/. Accessed July 3, 2018.
18.
US Department of Health and Human Services. HRSA Data Warehouse; Area Health Resource File: 2018. https://datawarehouse.hrsa.gov/topics/ahrf.aspx. Accessed July 3, 2018.
19.
Centers for Disease Control and Prevention. Drug Overdose Death Data. 2018. https://www.cdc.gov/drugoverdose/data/statedeaths.html. Accessed July 3, 2018.
20.
Karaca-Mandic  P, Norton  EC, Dowd  B.  Interaction terms in nonlinear models.  Health Serv Res. 2012;47(1, pt 1):255-274. doi:10.1111/j.1475-6773.2011.01314.xPubMedGoogle ScholarCrossref
21.
Williams  RL.  A note on robust variance estimation for cluster-correlated data.  Biometrics. 2000;56(2):645-646. doi:10.1111/j.0006-341X.2000.00645.xPubMedGoogle ScholarCrossref
22.
Sawilowsky  SS.  New effect size rules of thumb.  J Mod Appl Stat Methods. 2009;8(2):597-599. doi:10.22237/jmasm/1257035100Google ScholarCrossref
23.
Courtemanche  C, Marton  J, Ukert  B, Yelowitz  A, Zapata  D.  Early impacts of the Affordable Care Act on health insurance coverage in Medicaid expansion and non-expansion states.  J Policy Anal Manage. 2017;36(1):178-210. doi:10.1002/pam.21961PubMedGoogle ScholarCrossref
24.
Dugoff  EH, Schuler  M, Stuart  EA.  Generalizing observational study results: applying propensity score methods to complex surveys.  Health Serv Res. 2014;49(1):284-303. doi:10.1111/1475-6773.12090PubMedGoogle ScholarCrossref
25.
Centers for Disease and Control and Prevention. Annual surveillance report of drug-related risks and outcomes. https://stacks.cdc.gov/view/cdc/47832. Published 2017. Accessed March 1, 2018.
26.
Finley  A. Does Medicaid spur opioid abuse? Wall Street Journal. https://www.wsj.com/articles/does-medicaid-spur-opioid-abuse-1506289279. Published September 24, 2017. Accessed March 1, 2018.
27.
Baicker  K, Allen  HL, Wright  BJ, Finkelstein  AN.  The effect of Medicaid on medication use among poor adults: evidence from Oregon.  Health Aff (Millwood). 2017;36(12):2110-2114. doi:10.1377/hlthaff.2017.0925PubMedGoogle ScholarCrossref
28.
Maclean  JC, Saloner  B.  The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence From the Affordable Care Act. Cambridge, MA: National Bureau of Economic Research; 2017. doi:10.3386/w23342
29.
Feder  KA, Mojtabai  R, Krawczyk  N,  et al.  Trends in insurance coverage and treatment among persons with opioid use disorders following the Affordable Care Act.  Drug Alcohol Depend. 2017;179:271-274. doi:10.1016/j.drugalcdep.2017.07.015PubMedGoogle ScholarCrossref
30.
Wen  H, Schackman  BR, Aden  B, Bao  Y.  States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees.  Health Aff (Millwood). 2017;36(4):733-741. doi:10.1377/hlthaff.2016.1141PubMedGoogle ScholarCrossref
31.
National Conference on State Legislatures. Prescribing Policies: States Confront Opioid Overdose Epidemic. Washington, DC: National Conference on State Legislatures; 2017.
32.
Fornili  KS, Fogger  SA.  Nurse practitioner prescriptive authority for buprenorphine: from DATA 2000 to CARA 2016.  J Addict Nurs. 2017;28(1):43-48. doi:10.1097/JAN.0000000000000160PubMedGoogle ScholarCrossref
33.
Medicaid Payment Advisory Committee.  Medicaid and the Opioid Epidemic. Washington, DC: Medicaid Payment Advisory Committee; 2017.
34.
Griffith  K, Evans  L, Bor  J.  The Affordable Care Act reduced socioeconomic disparities in health care access.  Health Aff (Millwood). 2017;36(8):1503-1510. doi:10.1377/hlthaff.2017.0083PubMedGoogle ScholarCrossref
35.
Miller  S, Wherry  LR.  Health and access to care during the first 2 years of the ACA Medicaid expansions.  N Engl J Med. 2017;376(10):947-956. doi:10.1056/NEJMsa1612890PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements